Unlocking the potential of biosimilars in community oncology

Cancer Therapy Advisor

Today, biologics make up more than half of the oncologic therapies in the pipeline. 

More in the Media

Cencora's Brian Biehn Forecasts Big Changes for the US Biosimilar Space

December 10, 2023

CancerNetwork, Lisa Harrison

Addressing disparities through the Enhancing Oncology Model and the opportunity with medically integrated dispensing

October 10, 2022

Outsourcing Pharma

Recruitment tool pairs pharma firms with providers to boost patient connection 

July 18, 2022

Pharmaceutical Executive

Physician Practices Post-Pandemic: Q&A with AmerisourceBergen Leadership

July 06, 2021